The Asia Pacific Colorectal Cancer Screening Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).
Colorectal Cancer (CRC) happens when cancerous cells begin to develop and spread in the colon or rectum part of the digestive tract. Early cases can have no symptoms and begin with non-cancerous polyps' growth but can be found with screening testing. A colorectal cancer screening detects the disease in asymptomatic individuals over 45 at a high risk of developing the disease. The size and site of the cancer affect the CRC's symptoms. Significant disease symptoms include alterations in bowel habits, stool consistency, blood in the stool, and abdominal pain. The need for screening to enable early detection and treatment of the disease has grown due to the rising incidence of CRC.
Colorectal cancer is also termed colon or rectal cancer. Colon and rectal cancer diagnostics are researched and developed along the same lines as these are different merely on the basis of origin of cancer. Over the past decade, there has been an increase in colorectal cancer cases, which can be ascribed to lifestyle diseases, an aging population, and improper dietary habits.
According to GLOBOCAN statistics, China is expected to have 286,162 deaths attributable to colorectal cancer (CRC) and 555,477 new disease cases in 2020. In recent years, China has seen an increase in the disease burden of CRC, particularly in urban and eastern regions, due to population aging, socioeconomic development, and lifestyle changes. Due to rising disposable incomes throughout the region, there is a greater awareness of colorectal cancer. The market for colorectal cancer screening is expected to expand due to the region's rising prevalence and expanding awareness of the disease.
The China market dominated the Asia Pacific Colorectal Cancer Screening Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.6 billion by 2030. The Japan market is anticipated to grow at a CAGR of 5% during (2023 - 2030). Additionally, The India market would witness a CAGR of 6.3% during (2023 - 2030).
Based on Type, the market is segmented into Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Colorectal Cancer Screening Market is Projected to reach USD 22.2 Billion by 2030, at a CAGR of 4.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG).
By Type
By End-user
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 